Citigroup Begins Coverage on Repligen (RGEN) Posted by Donna Armstrong | Dec 18th, 2017 
Citigroup started coverage on shares of Repligen (NASDAQ:RGEN) in a research report issued on Friday, December 8th, MarketBeat.com reports. The brokerage set a "buy" rating and a $45.00 price target on the biotechnology company's stock. Citigroup's price objective would suggest a potential upside of 24.72% from the stock's previous close. 
Several other equities analysts have also weighed in on RGEN. Zacks Investment Research upgraded Repligen from a "hold" rating to a "buy" rating and set a $46.00 target price on the stock in a report on Saturday, August 12th. TheStreet upgraded Repligen from a "c+" rating to a "b-" rating in a research note on Friday, August 11th. Stephens reiterated an "overweight" rating and issued a $50.00 price objective on shares of Repligen in a research note on Tuesday, September 26th. J P Morgan Chase & Co initiated coverage on Repligen in a research note on Tuesday, December 5th. They issued an "overweight" rating and a $42.00 price objective on the stock. Finally, First Analysis raised Repligen from an "equal weight" rating to an "overweight" rating and set a $47.00 target price on the stock in a research report on Monday, October 2nd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of "Buy" and a consensus target price of $44.38. Get Repligen alerts: 
Shares of Repligen ( NASDAQ RGEN ) traded up $0.85 during trading on Friday, hitting $36.08. The stock had a trading volume of 896,000 shares, compared to its average volume of 327,414. The firm has a market capitalization of $1,571.83, a PE ratio of 62.21, a PEG ratio of 2.35 and a beta of 1.04. Repligen has a 1-year low of $28.48 and a 1-year high of $46.81. 
Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.11 by $0.04. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The business had revenue of $36.58 million during the quarter, compared to analyst estimates of $35.69 million. During the same period last year, the company earned $0.08 earnings per share. Repligen's quarterly revenue was up 48.2% compared to the same quarter last year. equities analysts forecast that Repligen will post 0.61 EPS for the current year. 
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lord Abbett & CO. LLC boosted its holdings in shares of Repligen by 330.9% in the 2nd quarter. Lord Abbett & CO. LLC now owns 851,360 shares of the biotechnology company's stock worth $35,280,000 after acquiring an additional 653,791 shares in the last quarter. TimesSquare Capital Management LLC raised its position in Repligen by 19.8% in the 2nd quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company's stock worth $97,851,000 after purchasing an additional 390,545 shares during the last quarter. William Blair Investment Management LLC raised its position in Repligen by 49.8% in the 2nd quarter. William Blair Investment Management LLC now owns 1,058,976 shares of the biotechnology company's stock worth $43,884,000 after purchasing an additional 352,045 shares during the last quarter. PointState Capital LP bought a new position in Repligen in the 2nd quarter worth approximately $11,984,000. Finally, Macquarie Group Ltd. raised its position in Repligen by 34.6% in the 3rd quarter. Macquarie Group Ltd. now owns 752,433 shares of the biotechnology company's stock worth $28,833,000 after purchasing an additional 193,232 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors. WARNING: "Citigroup Begins Coverage on Repligen (RGEN)" was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.thelincolnianonline.com/2017/12/18/repligen-rgen-coverage-initiated-by-analysts-at-citigroup-updated.html. 
About Repligen 
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products.   Repligen   Repligen
